Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H25ClN2OS.2ClH |
| Molecular Weight | 473.887 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC4=CC=C(Cl)C=C24)CC1
InChI
InChIKey=LPWNZMIBFHMYMX-MHKBYHAFSA-N
InChI=1S/C22H25ClN2OS.2ClH/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26;;/h1-2,4-8,16,26H,3,9-15H2;2*1H/b18-5-;;
| Molecular Formula | C22H25ClN2OS |
| Molecular Weight | 400.965 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6222099 | https://www.ncbi.nlm.nih.gov/pubmed/1965312http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdfCurator's Comment: Description was created based on several sources, including
https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6222099 | https://www.ncbi.nlm.nih.gov/pubmed/1965312http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf
Curator's Comment: Description was created based on several sources, including
https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987
Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. Zuclopenthixol, a thioxanthene derivative, has high affinity for both dopamine D1 receptors and
dopamine D2 receptors. Zuclopenthixol also has high affinity for α1-adrenergic and 5-HT2
receptors. Zuclopenthixol (CLOPIXOL®) is avavilable in the form of tablets and solution for intramuscular injections.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 |
|||
Target ID: CHEMBL2056 |
|||
Target ID: CHEMBL2094251 |
|||
Target ID: CHEMBL2093870 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CLOPIXOL Approved UseZuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. |
|||
| Primary | CLOPIXOL Approved UseZuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
100 mg 1 times / 2 days multiple, oral Recommended Dose: 100 mg, 1 times / 2 days Route: oral Route: multiple Dose: 100 mg, 1 times / 2 days Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Neuroleptic malignant syndrome Sources: |
600 mg 1 times / 4 weeks multiple, intramuscular Recommended Dose: 600 mg, 1 times / 4 weeks Route: intramuscular Route: multiple Dose: 600 mg, 1 times / 4 weeks Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Neuroleptic malignant syndrome | Disc. AE | 100 mg 1 times / 2 days multiple, oral Recommended Dose: 100 mg, 1 times / 2 days Route: oral Route: multiple Dose: 100 mg, 1 times / 2 days Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder. | 2014-05-15 |
|
| Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. | 2014-03 |
|
| Simultaneous determination of 25 common pharmaceuticals in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry. | 2012-09 |
|
| Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. | 2012-04-18 |
|
| Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. | 2010-04 |
|
| Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. | 2009-11-13 |
|
| Fatal exertional heat stroke in a patient receiving zuclopenthixol, quetiapine and benztropine. | 2007 |
|
| [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006-06 |
|
| Long term results of unilateral posteroventral pallidotomy for antipsychotic drug induced tardive dyskinesia. | 2005-07 |
|
| Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats. | 2004-08 |
|
| Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. | 2003-07 |
|
| Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs. | 2001-07 |
|
| Clozapine and weight gain. | 2001-05 |
|
| Effect of some psychotropic drugs and a barbiturate on mycoplasmas. | 2000-04 |
|
| Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. | 1995-11 |
|
| [acute dystonias in combined abuse of cocaine and neuroleptics]. | 1994-11-26 |
|
| Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. | 1991-12 |
|
| Reversible lithium neurotoxicity at normal serum level may refer to intracranial pathology. | 1989-05 |
|
| Zuclopenthixol and haloperidol/levomepromazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind, multi-centre study. | 1989 |
|
| Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study. | 1987-07 |
|
| Prolonged oculogyric crisis on addition of nifedipine to neuroleptic medication regime. | 1987-01 |
|
| The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. | 1986-12 |
|
| Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions. | 1984-07-13 |
|
| The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy. | 1967 |
Patents
Sample Use Guides
Clopixol tablets: The usual dose is 10 to 50 mg per
day.
Clopixol Acuphase injection: The usual dose is 50 to 150 mg (1 to 3 mL) every 2 to 3 days or as
instructed by your doctor.
Clopixol Depot injection: The usual dose is 200 to 400 mg (1 to 2 mL) every second to fourth week.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:16:45 GMT 2025
by
admin
on
Mon Mar 31 19:16:45 GMT 2025
|
| Record UNII |
7042692VYN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
58045-23-1
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
DTXSID5045332
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
C95837
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
261-080-2
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
m3653
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | Merck Index | ||
|
102546
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | RxNorm | ||
|
DBSALT000546
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
100000085645
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
6433208
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
7042692VYN
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
329015
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
SUB05197MIG
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |